Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 12/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HTR6 | P50406 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27933545 | 0.99 | SMN1; SMN2 (0.51) | SMN1; SMN2HPGDMAPTALDH1A1MAPK1 | |
| SCHEMBL1748292 | 0.82 | SMN1; SMN2 (0.77) | SMN1; SMN2HPGDMAPTALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL1748439 | 0.81 | SMN1; SMN2 (0.76) | SMN1; SMN2HPGDMAPTALDH1A1MAPK1 | |
| SCHEMBL5021183 | 0.80 | ALDH1A1 (0.47) | SMN1; SMN2MAPTALDH1A1MAPK1POLB | |
| SCHEMBL1748190 | 0.78 | HTR6 (0.56) | SMN1; SMN2MAPTALDH1A1MAPK1POLB | |
| SCHEMBL14941307 | 0.77 | LMNA (0.75) | SMN1; SMN2MAPTALDH1A1MAPK1POLB | |
| Hydrochloric Acid SCHEMBL1752646 | 0.77 | HTR6 (0.55) | SMN1; SMN2MAPTALDH1A1MAPK1POLB | |
| SCHEMBL1748559 | 0.76 | HTR6 (0.52) | SMN1; SMN2MAPTALDH1A1MAPK1POLB | |
| SCHEMBL7805747 | 0.73 | MAPT (0.60) | SMN1; SMN2MAPTALDH1A1MAPK1POLB | |
| SCHEMBL475719 | 0.73 | SMN1; SMN2 (0.79) | SMN1; SMN2HPGDMAPTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | claimed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | HTR6, HTR2A, HTR3B | SMN1; SMN2 3858/4885HPGD 2326/4885MAPT 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.